Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416571 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT01416571 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 78 participants.
The verdict
NCT01416571, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
Interventions
- BIOLOGICAL Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2011-08-12 |
| Est. Completion | 2012-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01416571
The ClinicalTrials.gov registry entry for NCT01416571 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is the first listed.
NCT01416571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01416571 about?
NCT01416571 is a clinical study titled "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults". This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
What is the current status of trial NCT01416571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2011-08-12. Estimated completion is 2012-09-28.
What interventions are being tested in trial NCT01416571?
The interventions under investigation include: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (BIOLOGICAL).
Who is sponsoring clinical trial NCT01416571?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.